Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Lung Neoplasms 26Prostatic Neoplasms 24Breast Neoplasms 17Carcinoma, Non-Small-Cell Lung 15Multiple Myeloma 14Sarcoma 12Leukemia, Myeloid, Acute 12Glioma 12Lymphoma, Non-Hodgkin 10Carcinoma, Hepatocellular 10Wilms Tumor 9Osteosarcoma 9Colorectal Neoplasms 9Rectal Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Ovarian Neoplasms 8Neuroblastoma 8Neoplasm Metastasis 8Myelodysplastic Syndromes 8Rhabdomyosarcoma 7Rhabdoid Tumor 7Pancreatic Neoplasms 7Mouth Neoplasms 7Medulloblastoma 7Hepatoblastoma 7Neuroectodermal Tumors, Primitive, Peripheral 6Melanoma 6Lymphoma 6Histiocytosis, Langerhans-Cell 6Head and Neck Neoplasms 6

Interventions

lutetium Lu 177 dotatate 1X-Rays 1Specimen Handling 1Photons 1Magnetic Resonance Spectroscopy 1Fluorodeoxyglucose F18 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Lung Neuroendocrine Tumor × X-Rays × Clear all
NCT04665739 2026-05-13

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

National Cancer Institute (NCI)

Phase 2 Recruiting
70 enrolled
EndocrineNET

Advanced Lung Neuroendocrine Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡